Literature DB >> 16304593

Can we prevent angle-closure glaucoma?

G J Johnson1, P J Foster.   

Abstract

PURPOSE: Glaucoma is the second cause, after cataract, of world blindness. Approximately half is thought to be primary angle-closure glaucoma (ACG). This review asks whether ACG can be prevented on a population basis. METHODS AND POPULATIONS: Review of published information from the Inuit of Greenland, Canada and Alaska, and descriptions of recent studies in Asian populations in Mongolia, China and South-East Asia.
RESULTS: The Greenland Inuit have the shallowest anterior chamber depths (ACDs) so far recorded. The proportion of blindness due to ACG was reduced from 64% to 9% over 37 years by systematic optical measurement of central ACD and the van Herick test in the older Inuit, followed by gonioscopy and prophylactic iridectomy or laser iridotomy when indicated. In Mongolia, ultrasound measurement of central ACD had good sensitivity and specificity as a screening test. A randomized controlled trial of screening and prophylactic laser is being completed. In China and South-East Asia, the mechanism of angle closure appears to be more varied and complex and its detection may require more elaborate imaging.
CONCLUSIONS: The mechanism of angle closure and potential for prevention by screening are likely to have to be determined specifically for each population at risk.

Entities:  

Mesh:

Year:  2005        PMID: 16304593     DOI: 10.1038/sj.eye.6701970

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  11 in total

1.  Nd: Yag laser iridotomy in Shaffer-Etienne grade 1 and 2: angle widening in our case studies.

Authors:  Sandra Cinzia Carlesimo; Luigi Di Santo; Pietro Bruni; Aloisa Librando; Antonietta Pompea Falace; Andrea Barbato
Journal:  Int J Ophthalmol       Date:  2015-08-18       Impact factor: 1.779

2.  Hong's grading for evaluating anterior chamber angle width.

Authors:  Seok Hwan Kim; Ja Heon Kang; Ki Ho Park; Chul Hong
Journal:  Jpn J Ophthalmol       Date:  2012-09-13       Impact factor: 2.447

3.  Pentacam could be a useful tool for evaluating and qualifying the anterior chamber morphology.

Authors:  Xiaoyu Li; Zheng Wang; Qun Cao; Lei Hu; Fang Tian; Hong Dai
Journal:  Int J Clin Exp Med       Date:  2014-07-15

Review 4.  Gonioscopy findings and prevalence of occludable angles in a Burmese population: the Meiktila Eye Study.

Authors:  R J Casson; H S Newland; J Muecke; S McGovern; L M Abraham; W K Shein; D Selva; T Aung
Journal:  Br J Ophthalmol       Date:  2007-07       Impact factor: 4.638

5.  Children's Ocular Components and Age, Gender, and Ethnicity.

Authors:  J Daniel Twelker; G Lynn Mitchell; Dawn H Messer; Rita Bhakta; Lisa A Jones; Donald O Mutti; Susuan A Cotter; Robert N Klenstein; Ruth E Manny; Karla Zadnik
Journal:  Optom Vis Sci       Date:  2009-08       Impact factor: 1.973

6.  Visual impairment and eye care among Alaska Native people.

Authors:  Sharon A Haymes; Jessica D Leston; Elizabeth D Ferucci; Ruth A Etzel; Anne P Lanier
Journal:  Ophthalmic Epidemiol       Date:  2009 May-Jun       Impact factor: 1.648

Review 7.  Prevalence of glaucoma in rural Myanmar: the Meiktila Eye Study.

Authors:  R J Casson; H S Newland; J Muecke; S McGovern; L Abraham; W K Shein; D Selva; T Aung
Journal:  Br J Ophthalmol       Date:  2007-06       Impact factor: 4.638

8.  Prevalence and determinants of glaucoma in citizens of qatar aged 40 years or older: a community-based survey.

Authors:  Fatma A Al-Mansouri; Aida Kanaan; Hamad Gamra; Rajiv Khandekar; Shakeel P Hashim; Omar Al Qahtani; Mohd Farouk Ahmed
Journal:  Middle East Afr J Ophthalmol       Date:  2011-04

9.  Enhancing the early differential diagnosis of plateau iris and pupillary block using a-scan ultrasonography.

Authors:  Yu-Yen Chen; Dachen Chu; Pesus Chou
Journal:  PLoS One       Date:  2015-02-17       Impact factor: 3.240

10.  Is Hyperopia an Important Risk Factor for PACG in the Dutch Population?-A Case Control Study.

Authors:  Saskia H M van Romunde; Gijs Thepass; Hans G Lemij
Journal:  J Ophthalmol       Date:  2013-09-15       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.